-
公开(公告)号：KR1020120060988A
公开(公告)日：2012-06-12
申请号：KR1020100097624
申请日：2010-10-07
Applicant: 한양대학교 산학협력단
Abstract: PURPOSE: A double-specific gene expression system for a neuroglial tissue and an ischemic tissue is provided to simultaneously recognize the tissues and to effectively treat or prevent ischemic cerebral diseases. CONSTITUTION: A double-specific recombinant vector for a neuroglial tissue and an ischemic tissue contains etythropoietin enhancer, nestin intron, promoter, and therapeutic agent for ischemic cerebral diseases. The enhancer contains a base of sequence number 1. The netin intron contains a base of sequence number 2. The promoter has an ischemic tissue-selective promoter sequence. The recombinant vector is a viral vector. A pharmaceutical composition for treating ischemic cerebral diseases contains the recombinant vector as an active ingredient.
Abstract translation: 目的：提供神经胶质组织和缺血组织的双特异性基因表达系统，以同时识别组织并有效治疗或预防缺血性脑疾病。 构成：用于神经胶质细胞和缺血组织的双特异性重组载体含有促红细胞生成素增强子，巢蛋白内含子，启动子和缺血性脑疾病的治疗剂。 增强子含有序列号1的碱基。网蛋白内含子含有序列号2的碱基。启动子具有缺血组织选择性启动子序列。 重组载体是病毒载体。 用于治疗缺血性脑疾病的药物组合物含有重组载体作为活性成分。
-
公开(公告)号：KR1020110138998A
公开(公告)日：2011-12-28
申请号：KR1020100059224
申请日：2010-06-22
Applicant: 한양대학교 산학협력단
Abstract: PURPOSE: An effective expression system of low oxygen-selective therapeutic gene using tyrosine hydroxylase 3' UTR is provided to treat ischemic diseases. CONSTITUTION: A recombinant vector for ischemia-specific expression contains a promoter, ischemia therapeutic gene, and tyrosine hydroxylase 3' UTR(untranslated region) sequence fused at the gene terminal. The ischemia therapeutic gene is a vascularization factor, such as basic fibroblast growth factor(bFGF), vascular endothelial growth factor(VEGF), plateletderived growth factor(PDGF), hepatocyte growth factor(HGF), heme oxygenase 1(HO-1), insulin growth factor(IGF-I or II), heat shock protein 27(HSP27), or tymidine kinase. A pharmaceutical composition for treating ischemia contains the recombinant vector as an active ingredient.
Abstract translation: 目的：提供使用酪氨酸羟化酶3'UTR的低氧选择性治疗基因的有效表达系统，用于治疗缺血性疾病。 构成：缺血特异性表达的重组载体含有在基因末端融合的启动子，缺血治疗基因和酪氨酸羟化酶3'UTR（非翻译区）序列。 缺血治疗基因是血管形成因子，如碱性成纤维细胞生长因子（bFGF），血管内皮生长因子（VEGF），血小板衍生生长因子（PDGF），肝细胞生长因子（HGF），血红素加氧酶1（HO-1） 胰岛素生长因子（IGF-I或II），热休克蛋白27（HSP27）或胸腺嘧啶激酶。 用于治疗缺血的药物组合物含有重组载体作为活性成分。
-
公开(公告)号：KR101588063B1
公开(公告)日：2016-01-22
申请号：KR1020100097624
申请日：2010-10-07
Applicant: 한양대학교 산학협력단
Abstract: 본발명은신경교조직및 허혈조직의 2중인지형유전자발현시스템에관한것으로, 뇌질환의저산소조건에서허혈성뇌질환치료유전자들이보다안정하게발현할수 있게하는특정에리트로포이에틴인핸서와네스틴인트론을이용한재조합벡터및 허혈성뇌질환치료용조성물등에관한것이다.
-
公开(公告)号：KR1020110139157A
公开(公告)日：2011-12-28
申请号：KR1020110060712
申请日：2011-06-22
Applicant: 한양대학교 산학협력단
Abstract: PURPOSE: An expression system of an ischemia therapeutic gene is provided to expression oxygen dependent degradation domain(ODD domain) sequence of ATF-4. CONSTITUTION: A recombinant expression vector contains a ischemia therapeutic gene and an oxygen dependent degradation domain(ODD domain) of ATF-4(activating transcription factor-4). The ischemia therapeutic gene is a vascularization factor. The ATF-4 ODDD sequence is derived from human and contains a base sequence of sequence number 1.
Abstract translation: 目的：提供缺血治疗基因的表达系统，以表达ATF-4的氧依赖性降解域（ODD域）序列。 构成：重组表达载体含有ATF-4（激活转录因子-4）的缺血治疗基因和氧依赖性降解结构域（ODD结构域）。 缺血治疗基因是血管化因子。 ATF-4 ODDD序列来源于人，含有序列号1的碱基序列。
-
-
-
Search Results
4
records
(took 0.02 seconds)
